Clinical trials: Tocilizumab
Refractory Cancer, Recurrent Cancer
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with…
- Conditions
- Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- Trial name
- NCT06372574
- Testing
- RO7617991, Tocilizumab
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether tocilizumab changes the cardiovascular risk factors on patients with arthritis rheumatoid.
- Trial name
- TOCRIVAR (NCT01752335)
- Testing
- Braquial ecography
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Universitario de Canarias
Multiple Myeloma
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab…
- Trial name
- CAMMA 1 (NCT04910568)
- Testing
- Cevostamab, Tocilizumab, Pomalidomide
- Where
- 34 sites in United States, Australia and 11 more
- Volunteers
- 186 people
- Sponsor
- Genentech, Inc.
Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus…
- Conditions
- Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections
- Trial name
- TOCIDEX (NCT04476979)
- Testing
- Tocilizumab, Dexamethasone
- Where
- French Guiana
- Volunteers
- 453 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
COVID19-associated disease may have different clinical aspects classified in 3 stages. Some patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve toward a more severe stage 2b or 3 (acute…
- Trial name
- INFLAMMACOV (NCT04424056)
- Testing
- Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Cholangiocarcinoma, Colorectal Cancer
TCR1188-ABC Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers.
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT07594067
- Testing
- TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Conditions
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
- Trial name
- NCT07709000
- Testing
- MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine)
- Where
- 5 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, Virus Diseases
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation.
- Conditions
- COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
- Trial name
- ESCAPE (NCT04339712)
- Testing
- Anakinra, Tocilizumab
- Where
- 17 sites in Greece
- Volunteers
- 102 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Rheumatoid Arthritis, JAK Inhibitor
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response…
- Conditions
- Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound
- Trial name
- TRANSFORM (NCT05090410)
- Testing
- filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Atsushi Kawakami
Multiple Myeloma, Relapsed Cancer
Plan Development for Giving Teclistamab in the Outpatient Setting
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient…
- Conditions
- Multiple Myeloma, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT06251076
- Testing
- Teclistamab, Tocilizumab
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University Health Network, Toronto
Covid19
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.
- Trial name
- COVITOZ-01 (NCT04435717)
- Testing
- Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1, Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Cerebral Venous Thrombosis
Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with…
- Trial name
- NCT07801638
- Testing
- Tocilizumab, Standard Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Capital Medical University
Rheumatoid Arthritis
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
This is a randomized, double-blind, multi-center, parallel-group study to evaluate the efficacy and safety of subcutaneous (SC) tocilizumab (162 milligrams [mg] every 2 weeks [Q2W]) given as monotherapy and in combination with…
- Trial name
- NCT03155347
- Testing
- Tocilizumab, MTX
- Where
- 20 sites in China
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT00810199
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 137 sites in United States, Brazil and 18 more
- Volunteers
- 556 people
- Sponsor
- Hoffmann-La Roche
Myocardial Infarction
Short-Term Application of Tocilizumab Following Myocardial Infarction
Introduction: Interleukin 6 (IL-6) is a cytokine that has a pro-inflammatory effect on the immune system. In acute MI IL-6 levels rapidly increase in response to ischemia and inflammation.
- Trial name
- STAT-MI (NCT02419937)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Keesler Air Force Base Medical Center
Arthritis,Rheumatoid
Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab
We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role.
- Trial name
- NCT02963402
- Testing
- Tocilizumab, Adalimumab
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Inflammatory Disease, Autoimmune Diseases
Personalized Therapies in Inflammatory Complex Disease
Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines.
- Trial name
- PIMOC (NCT03651518)
- Testing
- Kineret, Humira, Stelara
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pneumonia, Viral, Cytokine Storm
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19
The host response against the coronavirus 2 (SARS-CoV-2) appears to be mediated by a 'cytoquine storm' developing a systemic inflammatory mechanism and an acute respiratory distress syndrome (ARDS), in the form of a bilateral…
- Trial name
- ULTRA-COVID (NCT04394182)
- Testing
- Ultra-Low-dose radiotherapy, ventilatory support with oxygen therapy, Lopinavir/ritonavir
- Where
- 2 sites in Spain
- Volunteers
- 15 people
- Sponsor
- Fundacion GenesisCare
Chronic Lymphocytic Leukemia, Richter's Transformation
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
This research is being done to evaluate Glofitamab by itself or in combination with Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab as possible treatments for Chronic Lymphocytic Leukemia (CLL) that has transformed into…
- Trial name
- NCT06043674
- Testing
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Christine Ryan
Sepsis
Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial
PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments.
- Trial name
- PALETTE (NCT06381661)
- Testing
- Tocilizumab, Baricitinib, Anakinra
- Where
- 19 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris